Edwards Lifesciences Corp VP Unloads $2,140,840 in Stock (EW)
Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. unloaded 23,270 shares of Edwards Lifesciences Corp stock on the open market in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $92.00, for a total value of $2,140,840.00. Following the completion of the sale, the vice president now directly owns 20,721 shares in the company, valued at approximately $1,906,332. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on EW shares. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Edwards Lifesciences Corp has an average rating of “Buy” and an average price target of $90.00.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% during mid-day trading on Friday, hitting $91.97. The stock had a trading volume of 1,899,876 shares. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $94.50. The stock has a 50-day moving average of $85.98 and a 200-day moving average of $77.78. The company has a market cap of $9.712 billion and a price-to-earnings ratio of 13.02.
Edwards Lifesciences Corp (NYSE:EW) last announced its earnings results on Tuesday, July 29th. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.28 EPS for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.